No abstract available.
Blood Glucose* ; Humans ; Infant, Newborn ; Infant, Premature*

There have been no standard treatments for recurrent aphthous stomatitis, and clinical management is usually directed toward symptomatic relief. Recent immunological investigations have focused on possible imrnunopathogenesis of the disease. Several reparters suggested that levamisole, nonspecific immune-stimulator, had a beneficiaI effect in controlling attacks of recurrent a,phthous stomatitis and in reducing subsequent episodes. The present study was undertaken to evaluate the therapeutic effectiveness of levamisole in patients with recurrent aphthous stomatitis. A total of 8 patients who had had recurrent aphthous stomatitis for 2 to 20 years and who had experienced at least one episode per month were selected for this study from the department of dermatology, National Medical Center, through March 1979 to September 1979, Levamisole (Decaris') was given 150mg, p.o., once daily on 3 consecutive days every week for 2 months. Tbe results were as follows. 1) One patient had to have levamisole discontinued due to a high fever and exacerbations of tbe oral ulcerations. 2) 5 patients showed beneficial effects in reducing tbe number, frequency, pain and severity of recurrent aphthous stomatitis. 3') One patient showed no therapeutic response. 4) One patient, who has experienced new oral ulcerations continuously before starting levamisole, showed no recurrences of the lesions during the follow-up period of 3 months. 5) Side effects during levamisole administration were transient and generally mild, They included nausea, headache, dizziness and high fever.
Dermatology ; Dizziness ; Fever ; Follow-Up Studies ; Headache ; Humans ; Levamisole* ; Nausea ; Oral Ulcer ; Recurrence ; Stomatitis ; Stomatitis, Aphthous*

No abstract available.
Humans ; Rehabilitation* ; Rural Population* ; Stroke*

No abstract available.
Diabetic Foot*

No Abstract Available.
Allografts* ; Posterior Cruciate Ligament*

No abstract available.
Neurothekeoma* ; Scalp*

BACKGROUND: Studies of immune response for cancer have demonstrated that the antitumor immune response plays a role in competing against the growth of cancer cells and is frequently altered in advanced cancer. METHODS: We evaluated the changes of peripheral blood lymphocytes and their subsets during preoperative and postoperative periods according to the time sequence of the postoperative condition in gastrointestinal carcinoma patients. Lymphocyte surface markers were determined in 39 stomach cancer patients and 33 colon cancer patients by using the indirect immunofluorescence technique with monoclonal antibodies. The patient's body weights, hemoglobin, hematocrits, total protein, and albumin were also measured preoperatively at and 1, 3, 6, 12, 18, and 24 months postoperatively. RESULTS: There were significant differences of clinico-laboratory findings between the preoperative and the postoperative periods except for hemoglobin, total protein, and albumin in postoperative course. The total leukocyte count significantly decreased from the postoperative 6th month. The lymphocyte count significantly increased from the postoperative 3rd month. The granulocytes decreased significantly in the postoperative 6th month. The T cells and B cells decreased in the postoperative 3rd month and 1st month, respectively. CD8 increased in the postoperative 3rd month and NK cells also increased in the postoperative 3rd, 6th and 24th months. Other peripheral lymphocytes and their subsets showed no significant differences. The changes in the lymphocyte subsets according to stage were not statistically significant (p<0.005). CONCLUSIONS: The postoperative changes in lymphocytes, granulocytes, and NK cells were significantly different compared with preoperative levels, but these results did not correlate with postoperative survival and recurrence rate because of the short postoperative follow-up periods.
Antibodies, Monoclonal ; B-Lymphocytes ; Body Weight ; Colonic Neoplasms ; Fluorescent Antibody Technique, Indirect ; Follow-Up Studies ; Granulocytes ; Hematocrit ; Humans ; Killer Cells, Natural ; Leukocyte Count ; Lymphocyte Count ; Lymphocyte Subsets ; Lymphocytes* ; Postoperative Period ; Recurrence ; Stomach Neoplasms ; T-Lymphocytes

BACKGROUND: Alopecia areata (AA) is a non-scarring, autoimmune, inflammatory hair loss on the scalp and/or body. This disease affects both adults and children but there are limited data on AA in children than AA in adults. OBJECTIVE: The purpose of this retrospective study is to evaluate the clinical characteristics, disease associations and psychosomatic dynamics of pediatric AA for the past 5 years. METHODS: A retrospective study was performed on 120 out-patients under 14 years old who are diagnosed as alopecia areata in the department of dermatology from March, 2007 to February, 2012. RESULTS: The proportion of pediatric group in total alopecia areata was 20.2% (120/595). According to clinical records, the alopecia areata were of 111 patients (79.9%) followed by those with alopecia universalis (4 patients; 2.8%) and alopecia totalis (5 patients; 3.6%). The ratio of males (57 patients; 47.5%) to females (63 patients; 52.5%) was 1 : 1.11. Alopecia areata was seen most frequently in the school age group (69 patients; 57.5%) and the duration period was less than one year in most cases (79.2%). Family history of alopecia areata was observed in 10.8% (13/120). The only child or eldest child being overloaded with homework and has deficient parent-child relationships including familial discord was accounted as the most susceptible group. A multiple bald patch was 51.4% in alopecia areata and the most common associated disease was atopic dermatitis (26 patients; 21.7%). CONCLUSION: We observed several clinical features of the pediatric AA, including epidemiology, clinical characteristics and disease associations. This study provided useful data for future research regarding AA in children.
Adult ; Alopecia ; Alopecia Areata ; Child ; Dermatitis, Atopic ; Dermatology ; Female ; Hair ; Humans ; Male ; Only Child ; Outpatients ; Parent-Child Relations ; Retrospective Studies ; Scalp

T cell activation is a critical event for initiation and regulation of immune responses and inhibitors of such signaling pathways are clinically useful for the treatment of patients received allogratt and autoimmune disease. In the course of screening soil microorganisms from the forest of Cheju island in Korea for new immunosuppressive agent, one of Streptomyces species (CK-95441) was found to produce a new immunosuppressant, tautomycetin which also had antifungal activity. Tautomycetin showed the inhibition of T cell proliferation in murine mixed lymphocyte reaction (MLR) and T cell activation induced by concanavalin A. Tautomycetin also blocked the induction of IL-2 gene expression which was examined in Jurkat TAg cell line in which multiple NFAT-binding sites and minimal IL-2 promoter drive the production of B-galactosidase. Also, the level of inhibition in activation-induced IL-2 receptor expression by tautomycetin was greater than those by cyclosporin A measured by flow cytometry. But, Fas ligand-induced apoptosis in Jurkat cells was unaffected by tautomycetin which was measured by DNA fragmentation assay. These results suggested that tautomycetin will be able to be used as a potent immunosuppressive drug following organ transplantation.

Cerebral venous thrombosis is come from thromboplebitis of infectious origin and bland occlusion of cerebral vein by various causes. Although the main cause of cerebral venous thrombosis is thrombophlebitis, the bland occlusion causes it infrequently as a form of an infarct state. We report a case of cerebral venous infarction caused by splenectomy induced thrombocytosis.
Cerebral Veins ; Infarction ; Splenectomy ; Thrombocytosis* ; Thrombophlebitis ; Venous Thrombosis